[go: up one dir, main page]

WO2004028528A1 - Compositions d'acides amines destinees a ameliorer les fonctions centrales - Google Patents

Compositions d'acides amines destinees a ameliorer les fonctions centrales Download PDF

Info

Publication number
WO2004028528A1
WO2004028528A1 PCT/JP2003/012532 JP0312532W WO2004028528A1 WO 2004028528 A1 WO2004028528 A1 WO 2004028528A1 JP 0312532 W JP0312532 W JP 0312532W WO 2004028528 A1 WO2004028528 A1 WO 2004028528A1
Authority
WO
WIPO (PCT)
Prior art keywords
mol
amino acid
moles
composition
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/012532
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Abe
Hiroshi Tsuchita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
RIKEN
Original Assignee
Meiji Dairies Corp
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp, RIKEN filed Critical Meiji Dairies Corp
Priority to AU2003268700A priority Critical patent/AU2003268700A1/en
Priority to CA002500415A priority patent/CA2500415A1/fr
Priority to US10/529,753 priority patent/US20060128778A1/en
Priority to NZ539579A priority patent/NZ539579A/en
Priority to EP03748625A priority patent/EP1552826A4/fr
Publication of WO2004028528A1 publication Critical patent/WO2004028528A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an amino acid composition and an amino acid composition solution having a remarkable effect on the improvement of central function, and more particularly to a saliva secreted by a hornet (Vespa genus) larva.
  • the present invention relates to an amino acid composition and an amino acid composition solution which are contained in a liquid and can be administered for recovery from central fatigue and the like.
  • the present inventors have studied the saliva secreted by hornet larvae, clarified the composition of the amino acid composition contained therein, and studied the use thereof.
  • an amino acid composition designated as VAAM exhibited a motor function 3 ⁇ 41 action (Patent No. 2518692). It is useful for maintaining strength, nourishment, nourishment, and recovery from fatigue.
  • Serotonin one of the physiologically active amines, is abundantly contained in enterochromin cells such as the pineal gland, platelets, and intestine of J3 ⁇ 4, and plays an important role in controlling brain functions. Serotonin S in the brain is closely related to the function of the brain, and particularly at high concentrations, induces fatigue and induction of hypnosis, and in dependence, etc., it interacts with other brain amines such as dopamine. It is also known to decrease. Of course, it shows strong control of emotions and physical control.
  • Serotonin in the brain during human exercise is associated with an increase in blood tributophan following exercise. ⁇ It is suggested that it will increase. This is inferred from the weaving of increased fatigue, drowsiness and malaise associated with exercise. Such central fatigue, together with muscle fatigue, is considered to be a factor that hinders performance improvement during exercise. Disclosure of the invention
  • an object of the present invention is to provide an amino acid composition or an amino acid solution that can recover such central fatigue and improve the central function.
  • the present invention is characterized in that it comprises threonine, proline, glycine, parin, isoleucine, oral isin, tyrosine, phenylalanine, lysine, aspartic acid, serine, daltamic acid, alanine, methionine, tributofan, histidine and arginine.
  • the present invention includes an amino acid composition solution having a composition substantially the same as the above composition in a liquid phase, preferably a « ⁇ solution. Each amino acid in the composition or solution has a certain desirable compounding ratio as a key.
  • This amino acid composition and its amino acids are naturally derived and have virtually no side effects. Compared with other amino acid compositions, the effect of reducing serotonin concentration, which is a sign of central fatigue, is high. Has an action. Removal of one or more amino acids from this amino acid composition makes it difficult to improve the central function described above, except for amino acid compositions or amino acid solutions from which only tributofan has been removed, and is superior to the amino acid compositions or solutions. Has central function improving effect.
  • This amino acid composition or solution also desirably contains each amino acid in a specific preferred ratio as described above.
  • VAAM has a male function of motor function with a complex mechanism of action, and many functions such as enhancement of lipid metabolism, improvement of liver function, improvement of renal function, and increase of body temperature act as a comprehensive action As a result, it is considered that the motor function is improved. From this point of view, it is suggested that improvement of the central function is indispensable for improvement of motor function.
  • serotonin in the brain is a cause of central fatigue, and anorexia, drowsiness, malaise and fatigue caused by excessive exercise are considered to be caused by increased serotonin in the brain.
  • the first amino acid composition according to the present invention contains 17 kinds of amino acids as essential components, and it is particularly preferable that each amino acid is contained in a specific composition ratio. That is, 2 to 15 moles of threonine, 4 to 30 moles of proline, 7 to 20 moles of glycine, 4 to 8 moles of palin, 3 to 9 moles of isoleucine, 2 to 12 moles of leucine, 1 to 9 moles of tyrosine, 0 to 0 moles of phenylalanine.
  • the second amino acid composition according to the present invention contains 16 kinds of amino acids in a specific composition as essential components, and comprises a triphenylamine from the amino acid composition of the first invention. This composition is excluded, and the amino acid group containing no triflate The composition also has a central function improving action equal to or greater than that of the first invention.
  • each amino acid is an L-amino acid.
  • the amino acid compositions of the first and second inventions may be taken in powder form or may be dissolved in water and taken as water. Ingestion can also be via oral administration, rectal administration, intravenous injection, intravenous drip, etc.
  • composition In the case of oral administration, besides administering the composition itself, it is mixed with pharmaceutically acceptable carriers, excipients, and diluents and used as powders, granules, tablets, capsules, troches, etc. Is also good. Oral administration of the composition itself is desirable because solid powders and tablets may take time to absorb. In this case, it may be administered as the above-mentioned solution together with an appropriate additive, for example, a salt such as sodium chloride, a pH adjuster, and a chelating agent. When used as an injection, an appropriate buffer or isotonic agent may be added and dissolved in sterile distilled water.
  • an appropriate additive for example, a salt such as sodium chloride, a pH adjuster, and a chelating agent.
  • an appropriate buffer or isotonic agent may be added and dissolved in sterile distilled water.
  • the timing of ingestion is not particularly limited, and it can be taken at any time before or after the onset of central fatigue.
  • drinks in the form of a solution for example, soft drinks, powdered drinks, for nutritional fortification or nutritional supplementation
  • “Pharmaceutical beverage” for example, soft drinks, powdered drinks, for nutritional fortification or nutritional supplementation
  • the amino acid composition of the present invention has low toxicity, its dosage can be set widely, and it is usually 0.5 to 5 g at a time, preferably 1 to 2 at a time, depending on the administration method and purpose of use. g, l to 20 g, preferably 4 to 10 g per day.
  • the solution is administered or ingested as a solution, the solution is administered or ingested as a solution of about 0.5 to 10% by weight at a time, 10 to 1000 ml at a time, preferably 1 to 4% by weight at a time, 100 to 400 ml.
  • the amino acid compositions of the first and second inventions have a remarkable effect on the recovery of central fatigue by reducing the serotonin concentration, and furthermore, the amino acid compositions Since it is derived from natural amino acids, it has low toxicity and is extremely effective for improving central function.
  • the amino acid composition of the present invention is desirably used as a solution, particularly as an aqueous solution.
  • the solution of the first or second invention may be dissolved in water to prepare a solution, or Individual amino acids may be separately dissolved in water to achieve the above composition in solution.
  • FIG. 1 is a graph showing the relationship between VAAM, VAAM-one TRP, CAAM, and DW administered in Examples 1 and 2 and Comparative Examples 1 and 2, and serotonin concentration.
  • Example 1 of Example 1 in Table 1 was prepared by mixing a commercially available amino acid and dissolving in water with a composition containing a composition (V ⁇ ) having 17 kinds of amino acids in a predetermined composition.
  • Exercise experiment
  • mice Five-week-old ddy male mice (SPF) were grouped into groups of five, and after fasting for 12 hours in a clean room, L 8% VAAM was orally administered at a ratio of 37.5 pl Zg—body weight and allowed to stand for 30 minutes. The brain was excised from 5 of each mouse group. The tail of each of the remaining mice was put on a 0.3 g weight, and after swimming in a river pool at 35 ° C for 30 minutes, the mouse was immediately excised and the brain was removed.
  • SPF Five-week-old ddy male mice
  • the excised brains before and after swimming were immediately weighed and frozen with liquid nitrogen.
  • 0.1 M acetate buffer pH 4.5
  • the absorbance at 280 nm was measured using Hitachi High Performance Chromatography (L-6200) with Hitachi Absorbance Monitor (L-4000UV-VIS), and recorded using a Shimadzu chromato pad.
  • the column used was OD S—S i 1 ica (18 c—5, 4.6 250 mm), and the mobile phase was 0.1 M acetic acid containing 10% methanol and 1 mmol EDTA (ethylenediaminetetraacetic acid).
  • a buffer (pH 4.5) was used, and the flow rate was L OmlZcm. The measurement results are shown in the graph of FIG.
  • CAAM shown in Table 1 (Comparative Example 1) or distilled water (Comparative Example 2, DW) was used in place of the VAAM of Example 1, and administered to mice under the same conditions as in Example 1 and administered. Serotonin concentration was measured under the same conditions as in Example 1. The results are shown in the graph of FIG.
  • the measured serotonin concentrations before swimming were highest in the VAAM group in Example 1, lower in the CAAM group in Comparative Example 1, and lowest in the DW group in Comparative Example 2 (see Figure 1, graph Medium, 5-HT means serotonin).
  • the measured serotonin concentration after swimming was highest in the CAAM group of Comparative Example 1, followed by the DW group of Comparative Example 2, and was lowest in the VAAM group of Example 1 (see Figure 1). .

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition ou une solution d'acides aminés destinée à améliorer les fonctions centrales, qui contient thréonine, proline, glycine, valine, isoleucine, leucine, tyrosine, phénylalanine, lysine, acide aspartique, sérine, acide glutamique, alanine, méthionine, tryptophane, histidine et arginine ; et une composition d'acides aminés ou une solution d'acides aminés, dérivée de ladite composition, qui est obtenue par l'élimination de tryptophane. Ces compositions d'acides aminés, qui permettent d'améliorer les fonctions centrales, p. ex. guérir la fatigue, sont issues de matières naturelles et ne comportent pratiquement aucun effet secondaire.
PCT/JP2003/012532 2002-09-30 2003-09-30 Compositions d'acides amines destinees a ameliorer les fonctions centrales Ceased WO2004028528A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003268700A AU2003268700A1 (en) 2002-09-30 2003-09-30 Amino acid compositions for improving central functions
CA002500415A CA2500415A1 (fr) 2002-09-30 2003-09-30 Composition d'acide amine destinee a ameliorer les fonctions centrales
US10/529,753 US20060128778A1 (en) 2002-09-30 2003-09-30 Amino acid composition for improving central functions
NZ539579A NZ539579A (en) 2002-09-30 2003-09-30 Amino acid composition for improving central nervous function
EP03748625A EP1552826A4 (fr) 2002-09-30 2003-09-30 Compositions d'acides amines destinees a ameliorer les fonctions centrales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-286487 2002-09-30
JP2002286487A JP2004123564A (ja) 2002-09-30 2002-09-30 中枢機能改善用アミノ酸組成物

Publications (1)

Publication Number Publication Date
WO2004028528A1 true WO2004028528A1 (fr) 2004-04-08

Family

ID=32040606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/012532 Ceased WO2004028528A1 (fr) 2002-09-30 2003-09-30 Compositions d'acides amines destinees a ameliorer les fonctions centrales

Country Status (10)

Country Link
US (1) US20060128778A1 (fr)
EP (1) EP1552826A4 (fr)
JP (1) JP2004123564A (fr)
KR (1) KR20050072096A (fr)
CN (1) CN1703214A (fr)
AU (1) AU2003268700A1 (fr)
CA (1) CA2500415A1 (fr)
NZ (1) NZ539579A (fr)
TW (1) TW200410681A (fr)
WO (1) WO2004028528A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145239A1 (fr) * 2006-06-13 2007-12-21 Meiji Dairies Corporation Agent anti-fatigue contenant une composition d'acides aminés
WO2009057775A1 (fr) * 2007-10-31 2009-05-07 Meiji Dairies Corporation Agent antifatigue comprenant une composition d'acides aminés
US11045437B2 (en) 2018-08-27 2021-06-29 Ajinomoto Co., Inc. Composition for improving brain function

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4792730B2 (ja) * 2004-11-12 2011-10-12 味の素株式会社 抗疲労組成物
JP2008247896A (ja) * 2007-03-07 2008-10-16 Shizuokaken Koritsu Daigaku Hojin 透析患者用経口アミノ酸組成物
JPWO2010050168A1 (ja) * 2008-10-27 2012-03-29 味の素株式会社 バリン、イソロイシン、ロイシン固溶体およびその製造方法
CN103181920A (zh) * 2011-12-28 2013-07-03 吴顺字 一种防癌植物油的配方
MX368900B (es) * 2014-12-04 2019-10-21 Professional Dietetics Spa Composicion a base de aminoacidos para recuperacion de fibroelastina en tejidos conectivos dermicos.
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) * 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
JP7142284B2 (ja) * 2017-06-06 2022-09-27 株式会社らいむ 神経伸長促進剤
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3810123A1 (fr) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
JPWO2022244867A1 (fr) * 2021-05-21 2022-11-24

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54145219A (en) * 1978-04-24 1979-11-13 Massachusetts Inst Technology Composition for increasing dopamine and norepinephilin content within neurosynapse
EP0144051A2 (fr) * 1983-11-30 1985-06-12 Boehringer Mannheim Italia S.P.A. Supplément diététique influençant le sommeil
WO1988004926A1 (fr) * 1987-01-08 1988-07-14 Nastech Pharmaceutical Company, Inc. Administration d'aminoacides par voie nasale
JPH03128318A (ja) * 1989-06-14 1991-05-31 Rikagaku Kenkyusho 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
JPH06336432A (ja) * 1993-05-28 1994-12-06 Rikagaku Kenkyusho アドレナリン及びノルアドレナリン分泌促進組成物
WO1997025060A1 (fr) * 1996-01-09 1997-07-17 The Institute Of Physical And Chemical Research Compositions d'acides amines
WO2002034257A1 (fr) * 2000-10-27 2002-05-02 Meiji Dairies Corporation Agents de recuperation ou de prevention de la fatigue dans le systeme nerveux central et aliments de recuperation ou de prevention associes
WO2002076445A1 (fr) * 2001-03-23 2002-10-03 Ajinomoto Co., Inc. Agents utilises pour lutter contre les maladies provoquees par le stress et medicaments associes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019558A (en) * 1988-05-09 1991-05-28 Georges Cehovic Method for treating memory disturbances using arginine aspartate
JPH11304793A (ja) * 1998-04-27 1999-11-05 Taisho Pharmaceut Co Ltd 抗精神疲労活性物質の評価方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54145219A (en) * 1978-04-24 1979-11-13 Massachusetts Inst Technology Composition for increasing dopamine and norepinephilin content within neurosynapse
EP0144051A2 (fr) * 1983-11-30 1985-06-12 Boehringer Mannheim Italia S.P.A. Supplément diététique influençant le sommeil
WO1988004926A1 (fr) * 1987-01-08 1988-07-14 Nastech Pharmaceutical Company, Inc. Administration d'aminoacides par voie nasale
JPH03128318A (ja) * 1989-06-14 1991-05-31 Rikagaku Kenkyusho 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
JPH06336432A (ja) * 1993-05-28 1994-12-06 Rikagaku Kenkyusho アドレナリン及びノルアドレナリン分泌促進組成物
WO1997025060A1 (fr) * 1996-01-09 1997-07-17 The Institute Of Physical And Chemical Research Compositions d'acides amines
WO2002034257A1 (fr) * 2000-10-27 2002-05-02 Meiji Dairies Corporation Agents de recuperation ou de prevention de la fatigue dans le systeme nerveux central et aliments de recuperation ou de prevention associes
WO2002076445A1 (fr) * 2001-03-23 2002-10-03 Ajinomoto Co., Inc. Agents utilises pour lutter contre les maladies provoquees par le stress et medicaments associes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1552826A4 *
YAMAMOTO T.: "Diminished central fatigue by inhibition of the L-system transporter for the uptake of tryptophan", BRAIN RESEARCH BULLETIN, vol. 52, no. 1, 2000, pages 35 - 38, XP002909020 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145239A1 (fr) * 2006-06-13 2007-12-21 Meiji Dairies Corporation Agent anti-fatigue contenant une composition d'acides aminés
JP5775657B2 (ja) * 2006-06-13 2015-09-09 株式会社明治 アミノ酸組成物を含有する疲労防止剤
WO2009057775A1 (fr) * 2007-10-31 2009-05-07 Meiji Dairies Corporation Agent antifatigue comprenant une composition d'acides aminés
JP2014129394A (ja) * 2007-10-31 2014-07-10 Meiji Co Ltd アミノ酸組成物を含有する疲労防止剤
JP5775668B2 (ja) * 2007-10-31 2015-09-09 株式会社明治 アミノ酸組成物を含有する疲労防止剤
US11045437B2 (en) 2018-08-27 2021-06-29 Ajinomoto Co., Inc. Composition for improving brain function

Also Published As

Publication number Publication date
CA2500415A1 (fr) 2004-04-08
US20060128778A1 (en) 2006-06-15
EP1552826A1 (fr) 2005-07-13
AU2003268700A1 (en) 2004-04-19
KR20050072096A (ko) 2005-07-08
NZ539579A (en) 2007-04-27
TW200410681A (en) 2004-07-01
EP1552826A4 (fr) 2007-05-23
CN1703214A (zh) 2005-11-30
JP2004123564A (ja) 2004-04-22

Similar Documents

Publication Publication Date Title
WO2004028528A1 (fr) Compositions d'acides amines destinees a ameliorer les fonctions centrales
EP1629840B1 (fr) Composition d'acide amine et remplacement de fluide
KR950002150B1 (ko) 레보도파 메틸에스테르를 함유하는 제약 조성물
TWI775921B (zh) 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法
JP6431670B2 (ja) 筋肉疲労の回復を促進するためのアミノ酸含有組成物
WO2010041647A1 (fr) Agent d'amélioration de l'endurance physique, agent antifatigue ou agent de récupération de la fatigue comportant une composition d'acide aminé en tant qu'ingrédient actif
KR20020043437A (ko) 항피로조성물
KR19990077107A (ko) 아미노산 조성물
WO2002074302A1 (fr) Compositions d'acides amines utilisees pour ameliorer l'insuffisance hepatique
JP3814683B2 (ja) アミノ酸組成物
JP2001520994A (ja) 消化管疾患を治療するためにクマリン誘導体を用いる用途
WO2015046184A1 (fr) Agent améliorant la fonction hépatique et/ou agent améliorant la fonction pancréatique
JP4009682B2 (ja) アドレナリン及びノルアドレナリン分泌促進組成物
JP4873778B2 (ja) 抗疲労剤
JP5067160B2 (ja) 肝癌発生・進展抑制剤
JPWO2006006729A1 (ja) Ｃ型肝炎ウイルス陽性ヒト肝硬変患者用肝癌発生・進展抑制剤
WO2002074303A1 (fr) Compositions d'acides amines pour ameliorer l'insuffisance renale
Yamamoto et al. The effect of tryptophan deficiency in the brain on rat fatigue levels: A rat model of fatigue reduction
HK1075608A (en) Amino acid compositions for improving central functions
JP2010006764A (ja) タンパク同化促進剤
KR100523354B1 (ko) 지구성 운동시 피로억제 및 운동 수행 후 면역기능 향상을위한 약학적 조성물 또는 기능성 식품
CN1520826A (zh) 一种提高沙棘黄酮生物利用度的药用组合物
HK1084896A (en) Amino acid composition and fluid replacement
HK1084896B (en) Amino acid composition and fluid replacement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2500415

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057005544

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003268700

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003748625

Country of ref document: EP

Ref document number: 539579

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20038254751

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057005544

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003748625

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006128778

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10529753

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10529753

Country of ref document: US